PD-L1/B7-H1 Fc Chimera Protein 1019-B7-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemPD-L1/B7-H1 Fc Chimera Protein
CompanyR&D Systems, a Bio-Techne Brand
Price $428.00Supplier Page View Company Product Page
Catalog Number1019-B7-100
SpeciesMouse
Molecule NamePD-L1/B7-H1
Size100 ug
FormatLyophilized from a 0.2 µm filtered solution in PBS
NCBI Full Gene NameCD274 molecule, CD274 antigen
NCBI Gene AliasesPdcd1l1, hPD-L1, B7H1, PDL1, PD-L1, PDCD1L1, B7-H, A530045L16Rik, B7h1, PDCD1LG1, Pdcd1lg1, Pdl1
Purity>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 75-85 kDa, reducing conditions
Theoretical: 51.3 kDa (monomer)
ApplicationsBioactivity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Mouse PD-L1/B7-H1 Fc Chimera Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Sizes Available: 100 ug

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) CD8 T cells mediate immunosurveillance for neoantigen+ epithelial stem cells in the colonbioRxivOctober 23, 2025Jessica Buck, Nivedita R. Iyer, Eric Fagerberg, Goran Micevic, Jiaming He, Kerri St. Denis, Vyom Shah, Holly Nicole Blackburn, Srividhya Venkatesan, John Attanasio, et al.μg/ml CD3 and 3 μg/ml CD28, with either recombinant 20 μg/ml PDL1 Fc chimera protein (R&D Systems, 1019-B7–100) or 10 μg/ml (equal molar ratio) recombinant human IgG1 Fc protein as a control (R&D Systems, 10-HG-100).

(2) A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent MiceBiomoleculesMarch 24, 2025Perrine Jacquot, Javier Muñoz-Garcia, Antoine Léger, Antoine Babuty, Manon Taupin, Laurie Fradet, Fabio Dupont, Marie-Françoise Heymann, Mathieu Cinier, Dominique Heymann(#1280-ER-050, R&D Systems, Minneapolis, MN, USA) and 5 µg/mL recombinant mouse PDL1/B7-H1 Fc chimera protein (#1019-B7-100, R&D Systems) at 2 nm on protein A biosensors (#18-5012, Sartorius). All measurement steps were performed

(3) Delivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of gliomaMaterials Today BioOctober 1, 2024Shang-Wen Lin, Cheng-Ping Yu, Jui-Chen Tsai, Yan-Jye Shyongfrom BioLegend (San Diego, CA, USA). The recombinant mouse PD-L1/B7-H1 chimera protein (catalog number 1019-B7-100) and mouse IL-18 ELISA kit were purchased from R&D Systems (Minneapolis, MN, USA). Biotin-conjugated

(4) Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune CheckpointACS nanoJanuary 16, 2024Paloja K, Weiden J, Hellmeier J, Eklund AS, Reinhardt SCM, Parish IA, Jungmann R, Bastings MMC.Bio-Techne Corporation (Minneapolis, MN, USA) provided recombinant mouse PD-L1-Fc protein (R&D systems, 1019-B7–100). Alamanda polymers (Huntsville, AL, USA) provided K10-PEG1K (mPEG1K-b-PLKC10). Ibidi GmbH (Gräfelfing,

(5) Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunityCell reportsOctober 31, 2023Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, et al.

(6) Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8(+) T cellsNature immunologyMay 1, 2023Corria-Osorio J, Carmona SJ, Stefanidis E, Andreatta M, Ortiz-Miranda Y, Muller T, Rota IA, Crespo I, Seijo B, Castro W, et al.

(7) Neuronally expressed PDL1, not PD1, suppresses acute nociceptionBrain, behavior, and immunityNovember 1, 2022Meerschaert KA, Edwards BS, Epouhe AY, Jefferson B, Friedman R, Babyok OL, Moy JK, Kehinde F, Liu C, Workman CJ, et al.recombinant mouse PD1 was purchased from Abcam (ab180051) and recombinant mouse PDL1 from R&D systems (1019B7100); the stock solutions were 400μg/ml and 100μg/ml, respectively. PD1 and PDL1 were dissolved in PBS with

(8) Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cellsScientific reportsJuly 21, 2022Martins C, Silva M, Rasbach E, Singh P, Itoh Y, Williams JB, Statham E, Meurer A, Martinez DV, Brandenburg A, et al.

(9) Computational design of a synthetic PD-1 agonistProceedings of the National Academy of Sciences of the United States of AmericaJuly 20, 2021Bryan CM, Rocklin GJ, Bick MJ, Ford A, Majri-Morrison S, Kroll AV, Miller CJ, Carter L, Goreshnik I, Kang A, et al.

(10) PD-L1⁺ neutrophils contribute to injury-induced infection susceptibilityScience advancesMarch 1, 2021Thanabalasuriar A, Chiang AJ, Morehouse C, Camara M, Hawkins S, Keller AE, Koksal AC, Caceres CS, Berlin AA, Holoweckyj N, et al.

(11) Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancermAbsJanuary 1, 2021Schofield DJ, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, McGlinchey K, Adjei G, Watkins A, Machiesky L, et al.injected subcutaneously with 20 µg of recombinant mouse PD-L1–Fc fusion protein (R&D Systems, catalog no. 1019-B7-100) in Freund complete adjuvant (Sigma-Aldrich). Three subsequent subcutaneous booster injections of 20

(12) Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAsPharmaceuticsJune 26, 2020Zalba S, Contreras-Sandoval AM, Martisova E, Debets R, Smerdou C, Garrido MJ.

(13) ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical modelsPloS oneJanuary 1, 2020Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, et al.

(14) Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complexPloS oneJanuary 1, 2020Garrett-Thomson SC, Massimi A, Fedorov EV, Bonanno JB, Scandiuzzi L, Hillerich B, Seidel RD 3rd, Love JD, Garforth SJ, Guha C, et al.

(15) Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cellsCancer scienceOctober 1, 2019Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K.

(16) Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and AutoimmunityCell reportsSeptember 24, 2019Garo LP, Ajay AK, Fujiwara M, Beynon V, Kuhn C, Gabriely G, Sadhukan S, Raheja R, Rubino S, Weiner HL, et al.Proteins,Recombinant Proteins,Recombinant Proteins "Mouse PDL1-Fc Chimera Protein, CF",R&D systems,Cat#1019-B7–100 "Mouse PDL2-Fc Chimera Protein, CF",R&D systems,Cat#1022-PL-100 GM-CSF,R&D systems,Cat#415-ML-010 IL-4,R&D systems

(17) Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse SepsisTheranosticsJanuary 1, 2019von Knethen A, Schäfer A, Kuchler L, Knape T, Christen U, Hintermann E, Fißlthaler B, Schröder K, Brandes RP, Genz B, et al.

(18) Indirubin attenuates mouse psoriasis-like skin lesion in a CD274-dependent manner: an achievement of RNA sequencingBioscience reportsDecember 21, 2018Xue X, Wu J, Li J, Xu J, Dai H, Tao C, Li C, Hu J.

(19) Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1Molecular cancer therapeuticsSeptember 1, 2018Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K, Ohkawara T, et al.

(20) Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor MicroenvironmentCancer researchSeptember 1, 2018Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y, Oshiumi H.

Be the First to Write a Review!

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein

PD-L1/B7-H1 Fc Chimera Protein from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (28)

Reviews

PD-L1/B7-H1 Fc Chimera Protein from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map